Abeta, oxidative stress in Alzheimer disease: Evidence based on proteomics studies

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1842, Issue 8, 2014, Pages 1248-1257

  Swomley, Aaron M ^a,b   Förster, Sarah ^c   Keeney, Jierel T ^a,b   Triplett, Judy ^a,b   Zhang, Zhaoshu ^a,b   Sultana, Rukhsana ^a,b   Butterfield, D Allan ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF BONN   (Germany)

Author keywords

Alzheimer disease; Amyloid ; Methionine 35; Oxidative stress; Redox proteomics

Indexed keywords

ACTIN; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID PRECURSOR PROTEIN; ANTIOXIDANT; BIOLOGICAL MARKER; COLLAPSIN RESPONSE MEDIATOR PROTEIN 2; ENOLASE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; METHIONINE; PROTEIN 14 3 3; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; REACTIVE OXYGEN METABOLITE; TUBULIN; 3 NITROTYROSINE; 4 HYDROXYNONENAL; ALPHA ENOLASE; ALPHA SECRETASE; ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN[25-35]; ARACHIDONIC ACID; ASCORBIC ACID; BETA SECRETASE; BETA TUBULIN; COPPER ZINC SUPEROXIDE DISMUTASE; CREATINE KINASE; FODRIN; FREE RADICAL; GAMMA SECRETASE; HEAT SHOCK PROTEIN 70; LACTATE DEHYDROGENASE; MANGANESE SUPEROXIDE DISMUTASE; PEPTIDYLPROLYL ISOMERASE PIN1; PROTEASOME; REACTIVE NITROGEN SPECIES; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANTIOXIDANT ACTIVITY; BEHAVIOR DISORDER; BRAIN CELL CULTURE; CAENORHABDITIS ELEGANS; CELL CULTURE MONITORING; DIET SUPPLEMENTATION; ENERGY METABOLISM; EVIDENCE BASED PRACTICE; HUMAN; MOUSE MODEL; NERVE DEGENERATION; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PATIENT; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION; SYNAPTOGENESIS; VITAMIN SUPPLEMENTATION; AUTOOXIDATION; CELL CYCLE PROGRESSION; CELL FUNCTION; CELL STRUCTURE; CHOLINERGIC TRANSMISSION; CLATHRIN MEDIATED ENDOCYTOSIS; COGNITIVE DEFECT; DOWN REGULATION; ENDOCYTOSIS; ENERGY RESOURCE; ENERGY YIELD; GENE EXPRESSION; GLUCOSE UTILIZATION; LATE STAGE ALZHEIMER DISEASE; LIPID BILAYER; LIPID PEROXIDATION; MICROGLIA; MILD COGNITIVE IMPAIRMENT; MITOCHONDRION; NERVE CELL CULTURE; NEUROFIBRILLARY TANGLE; NITROSATIVE STRESS; POSITRON EMISSION TOMOGRAPHY; PRE CLINICAL ALZHEIMER DISEASE; RESPIRATORY CHAIN; SYNAPSE;

ALZHEIMER DISEASE; AMYLOID-Β; METHIONINE-35; OXIDATIVE STRESS; REDOX PROTEOMICS;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIOXIDANTS; DISEASE MODELS, ANIMAL; HUMANS; OXIDATIVE STRESS; PROTEOMICS;

EID: 84903276737     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2013.09.015     Document Type: Review

References (145)

1. Hebert L.E., Scherr P.A., Bienias J.L., Bennett D.A., Evans D.A. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch. Neurol. 2003, 60:1119-1122.
2. Butterfield D.A., Lauderback C.M. Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radic. Biol. Med. 2002, 32:1050-1060.
3. Uttara B., Singh A.V., Zamboni P., Mahajan R.T. Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr. Neuropharmacol. 2009, 7:65-74.
4. Vos S.J., van Rossum I.A., Verhey F., Knol D.L., Soininen H., Wahlund L.O., Hampel H., Tsolaki M., Minthon L., Frisoni G.B., Froelich L., Nobili F., van der Flier W., Blennow K., Wolz R., Scheltens P., Visser P.J. Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI. Neurology 2013, 80:1124-1132.
5. Sultana R., Butterfield D.A. Role of oxidative stress in the progression of Alzheimer's disease. J. Alzheimers Dis. 2010, 19:341-353.
6. Dasuri K., Zhang L., Keller J.N. Oxidative stress, neurodegeneration, and the balance of protein degradation and protein synthesis. Free Radic. Biol. Med. 2012, 62:170-185.
7. Sies H. Oxidative stress: oxidants and antioxidants. Exp. Physiol. 1997, 82:291-295.
8. Schulz E., Wenzel P., Munzel T., Daiber A. Mitochondrial redox signaling: interaction of mitochondrial reactive oxygen species with other sources of oxidative stress. Antioxid. Redox Signal. 2012, (in press) (ahead of print).
9. Halliwell B. Free radicals and antioxidants: updating a personal view. Nutr. Rev. 2012, 70:257-265.
10. Valko M., Leibfritz D., Moncol J., Cronin M.T., Mazur M., Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol. 2007, 39:44-84.
11. Butterfield D.A., Dalle-Donne I. Redox proteomics. Antioxid. Redox Signal. 2012, 17:1487-1489.
12. Hensley K., Williamson K.S., Floyd R.A. Measurement of 3-nitrotyrosine and 5-nitro-gamma-tocopherol by high-performance liquid chromatography with electrochemical detection. Free Radic. Biol. Med. 2000, 28:520-528.
13. Williamson K.S., Gabbita S.P., Mou S., West M., Pye Q.N., Markesbery W.R., Cooney R.V., Grammas P., Reimann-Philipp U., Floyd R.A., Hensley K. The nitration product 5-nitro-gamma-tocopherol is increased in the Alzheimer brain. Nitric Oxide Biol. Chem. 2002, 6:221-227.
14. Adam-Vizi V. Production of reactive oxygen species in brain mitochondria: contribution by electron transport chain and non-electron transport chain sources. Antioxid. Redox Signal. 2005, 7:1140-1149.
15. Calabrese V., Lodi R., Tonon C., D'Agata V., Sapienza M., Scapagnini G., Mangiameli A., Pennisi G., Stella A.M., Butterfield D.A. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia. J. Neurol. Sci. 2005, 233:145-162.
16. De Giusti V.C., Caldiz C.I., Ennis I.E., Perez N.G., Cingolani H.E., Aiello E.A. Mitochondrial reactive oxygen species (ROS) as signaling molecules of intracellular pathways triggered by the cardiac renin-angiotensin II-aldosterone system (RAAS). Front. Physiol. 2013, 4:126.
17. Scialo F Mallikarjun V Stefanatos R Sanz A, Regulation of life span by the mitochondrial electron transport chain: reactive oxygen species-dependent and reactive oxygen species-independent mechanisms, Antioxidants and Redox Signaling. 2013, volume 19 issue 16 page number 1953-1969
18. Fridovich I. Biological effects of the superoxide radical. Arch. Biochem. Biophys. 1986, 247:1-11.
19. Deby C., Goutier R. New perspectives on the biochemistry of superoxide anion and the efficiency of superoxide dismutases. Biochem. Pharmacol. 1990, 39:399-405.
20. Halliwell B., Gutteridge J.M. Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem. J. 1984, 219:1-14.
21. Klamt F., Gottfried C., Tramontina F., Dal-Pizzol F., Da Frota M.L., Moreira J.C., Dias R.D., Moriguchi E., Wofchuk S., Souza D.O. Time-related increase in mitochondrial superoxide production, biomolecule damage and antioxidant enzyme activities in cortical astrocyte cultures. Neuroreport 2002, 13:1515-1518.
22. Tangpong J., Sompol P., Vore M., St Clair W., Butterfield D.A., St Clair D.K. Tumor necrosis factor alpha-mediated nitric oxide production enhances manganese superoxide dismutase nitration and mitochondrial dysfunction in primary neurons: an insight into the role of glial cells. Neuroscience 2008, 151:622-629.
23. Aluise C.D., Miriyala S., Noel T., Sultana R., Jungsuwadee P., Taylor T.J., Cai J., Pierce W.M., Vore M., Moscow J.A., St Clair D.K., Butterfield D.A. 2-Mercaptoethane sulfonate prevents doxorubicin-induced plasma protein oxidation and TNF-alpha release: implications for the reactive oxygen species-mediated mechanisms of chemobrain. Free Radic. Biol. Med. 2011, 50:1630-1638.
24. Dean R.T., Fu S., Stocker R., Davies M.J. Biochemistry and pathology of radical-mediated protein oxidation. Biochem. J. 1997, 324(Pt 1):1-18.
25. Bader Lange M.L., St Clair D., Markesbery W.R., Studzinski C.M., Murphy M.P., Butterfield D.A. Age-related loss of phospholipid asymmetry in APP(NLh)/APP(NLh)×PS-1(P264L)/PS-1(P264L) human double mutant knock-in mice: relevance to Alzheimer disease. Neurobiol. Dis. 2010, 38:104-115.
26. Castegna A., Lauderback C.M., Mohmmad-Abdul H., Butterfield D.A. Modulation of phospholipid asymmetry in synaptosomal membranes by the lipid peroxidation products, 4-hydroxynonenal and acrolein: implications for Alzheimer's disease. Brain Res. 2004, 1004:193-197.
27. Butterfield D.A., Bader Lange M.L., Sultana R. Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease. Biochim. Biophys. Acta 2010, 1801:924-929.
28. Perluigi M., Coccia R., Butterfield D.A. 4-Hydroxy-2-nonenal, a reactive product of lipid peroxidation, and neurodegenerative diseases: a toxic combination illuminated by redox proteomics studies. Antioxid. Redox Signal. 2012, 17:1590-1609.
29. Frisardi V., Panza F., Seripa D., Farooqui T., Farooqui A.A. Glycerophospholipids and glycerophospholipid-derived lipid mediators: a complex meshwork in Alzheimer's disease pathology. Prog. Lipid Res. 2011, 50:313-330.
30. Jones P.M., Persaud S.J. Arachidonic acid as a second messenger in glucose-induced insulin secretion from pancreatic beta-cells. J. Endocrinol. 1993, 137:7-14.
31. 2+, cAMP, and phospholipid-derived messengers in coupling mechanisms of insulin secretion. Physiol. Rev. 1987, 67:1185-1248.
32. Varadarajan S., Yatin S., Aksenova M., Butterfield D.A. Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. J. Struct. Biol. 2000, 130:184-208.
33. Yatin S.M., Varadarajan S., Butterfield D.A. Vitamin E prevents Alzheimer's amyloid beta-peptide (1-42)-induced neuronal protein oxidation and reactive oxygen species production. J. Alzheimers Dis. 2000, 2:123-131.
34. Butterfield D.A. beta-Amyloid-associated free radical oxidative stress and neurotoxicity: implications for Alzheimer's disease. Chem. Res. Toxicol. 1997, 10:495-506.
35. Butterfield D.A., Stadtman E.R. Protein oxidation processes in aging brain. Adv. Cell Aging Gerontol. 1997, 2:161-191.
36. Lauderback C.M., Hackett J.M., Huang F.F., Keller J.N., Szweda L.I., Markesbery W.R., Butterfield D.A. The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Abeta1-42. J. Neurochem. 2001, 78:413-416.
37. Harris M.E., Hensley K., Butterfield D.A., Leedle R.A., Carney J.M. Direct evidence of oxidative injury produced by the Alzheimer's beta-amyloid peptide (1-40) in cultured hippocampal neurons. Exp. Neurol. 1995, 131:193-202.
38. Boyd-Kimball D., Sultana R., Poon H.F., Lynn B.C., Casamenti F., Pepeu G., Klein J.B., Butterfield D.A. Proteomic identification of proteins specifically oxidized by intracerebral injection of amyloid beta-peptide (1-42) into rat brain: implications for Alzheimer's disease. Neuroscience 2005, 132:313-324.
39. Butterfield D.A., Castegna A., Lauderback C.M., Drake J. Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death. Neurobiol. Aging 2002, 23:655-664.
40. Shinde U.A., Mehta A.A., Goyal R.K. Nitric oxide: a molecule of the millennium. Indian J. Exp. Biol. 2000, 38:201-210.
41. Xu W., Charles I.G., Moncada S., Gorman P., Sheer D., Liu L., Emson P. Mapping of the genes encoding human inducible and endothelial nitric oxide synthase (NOS2 and NOS3) to the pericentric region of chromosome 17 and to chromosome 7, respectively. Genomics 1994, 21:419-422.
42. McCarty M.F. Down-regulation of microglial activation may represent a practical strategy for combating neurodegenerative disorders. Med. Hypotheses 2006, 67:251-269.
43. Moller M.N., Li Q., Lancaster J.R., Denicola A. Acceleration of nitric oxide autoxidation and nitrosation by membranes. IUBMB Life 2007, 59:243-248.
44. 2within the hydrophobic interior of biological membranes. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:2175-2179.
45. Feeney M.B., Schoneich C. Tyrosine modifications in aging. Antioxid. Redox Signal. 2012, 17:1571-1579.
46. MacMillan-Crow L.A., Crow J.P., Thompson J.A. Peroxynitrite-mediated inactivation of manganese superoxide dismutase involves nitration and oxidation of critical tyrosine residues. Biochemistry 1998, 37:1613-1622.
47. Surmeli N.B., Litterman N.K., Miller A.F., Groves J.T. Peroxynitrite mediates active site tyrosine nitration in manganese superoxide dismutase. Evidence of a role for the carbonate radical anion. J. Am. Chem. Soc. 2010, 132:17174-17185.
48. Ischiropoulos H. Protein tyrosine nitration - an update. Arch. Biochem. Biophys. 2009, 484:117-121.
49. Amirmansour C., Vallance P., Bogle R.G. Tyrosine nitration in blood vessels occurs with increasing nitric oxide concentration. Br. J. Pharmacol. 1999, 127:788-794.
50. Surmeli N.B., Litterman N.K., Miller A.F., Groves J.T. Peroxynitrite mediates active site tyrosine nitration in manganese superoxide dismutase. Evidence of a role for the carbonate radical anion. J. Am. Chem. Soc. 2010, 132:17174-17185.
51. Reed T.T., Pierce W.M., Turner D.M., Markesbery W.R., Butterfield D.A. Proteomic identification of nitrated brain proteins in early Alzheimer's disease inferior parietal lobule. J. Cell Mol. Med. 2009, 13:2019-2029.
52. Reed T.T., Pierce W.M., Markesbery W.R., Butterfield D.A. Proteomic identification of HNE-bound proteins in early Alzheimer disease: insights into the role of lipid peroxidation in the progression of AD. Brain Res. 2009, 1274:66-76.
53. O'Brien R.J., Wong P.C. Amyloid precursor protein processing and Alzheimer's disease. Ann. Rev. Neurosci. 2011, 34:185-204.
54. Zheng H., Koo E.H. The amyloid precursor protein: beyond amyloid. Mol. Neurodegener. 2006, 1:5.
55. Billnitzer A.J., Barskaya I., Yin C., Perez R.G. APP independent and dependent effects on neurite outgrowth are modulated by the receptor associated protein (RAP). J. Neurochem. 2013, 124:123-132.
56. Grimm M.O., Haupenthal V.J., Rothhaar T.L., Zimmer V.C., Grosgen S., Hundsdorfer B., Lehmann J., Grimm H.S., Hartmann T. Effect of different phospholipids on alpha-secretase activity in the non-amyloidogenic pathway of Alzheimer's disease. Int. J. Mol. Sci. 2013, 14:5879-5898.
57. Kamenetz F., Tomita T., Hsieh H., Seabrook G., Borchelt D., Iwatsubo T., Sisodia S., Malinow R. APP processing and synaptic function. Neuron 2003, 37:925-937.
58. Hartlage-Rubsamen M., Waniek A., Rossner S. Munc13 genotype regulates secretory amyloid precursor protein processing via postsynaptic glutamate receptors. Int. J. Dev. Neurosci. 2013, 31:36-45.
59. Gustafsen C., Glerup S., Pallesen L.T., Olsen D., Andersen O.M., Nykjaer A., Madsen P., Petersen C.M. Sortilin and SorLA display distinct roles in processing and trafficking of amyloid precursor protein. J. Neurosci. 2013, 33:64-71.
60. Lichtenthaler S.F. Alpha-secretase cleavage of the amyloid precursor protein: proteolysis regulated by signaling pathways and protein trafficking. Curr. Alzheimer Res. 2012, 9:165-177.
61. Marcello E., Gardoni F., Mauceri D., Romorini S., Jeromin A., Epis R., Borroni B., Cattabeni F., Sala C., Padovani A., Di Luca M. Synapse-associated protein-97 mediates alpha-secretase ADAM10 trafficking and promotes its activity. J. Neurosci. 2007, 27:1682-1691.
62. Marcello E., Epis R., Saraceno C., Gardoni F., Borroni B., Cattabeni F., Padovani A., Di Luca M. SAP97-mediated local trafficking is altered in Alzheimer disease patients' hippocampus. Neurobiol. Aging 2012, 33(422):e421-410. 10.1016/j.neurobiolaging.2010.09.015.
63. Vingtdeux V., Marambaud P. Identification and biology of alpha-secretase. J. Neurochem. 2012, 120(Suppl. 1):34-45.
64. Ortega F., Stott J., Visser S.A., Bendtsen C. Interplay between alpha-, beta-, and gamma-secretases determines biphasic amyloid-beta protein level in the presence of a gamma-secretase inhibitor. J. Biol. Chem. 2013, 288:785-792.
65. Rodrigues E.M., Weissmiller A.M., Goldstein L.S. Enhanced beta-secretase processing alters APP axonal transport and leads to axonal defects. Hum. Mol. Genet. 2012, 21:4587-4601.
66. Nikolaev A., McLaughlin T., O'Leary D.D., Tessier-Lavigne M. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 2009, 457:981-989.
67. Sutinen E.M., Pirttila T., Anderson G., Salminen A., Ojala J.O. Pro-inflammatory interleukin-18 increases Alzheimer's disease-associated amyloid-beta production in human neuron-like cells. J. Neuroinflammation 2012, 9:199.
68. Venugopal C., Demos C.M., Rao K.S., Pappolla M.A., Sambamurti K. Beta-secretase: structure, function, and evolution. CNS Neurol. Disord. Drug Targets 2008, 7:278-294.
69. Marquer C., Devauges V., Cossec J.C., Liot G., Lecart S., Saudou F., Duyckaerts C., Leveque-Fort S., Potier M.C. Local cholesterol increase triggers amyloid precursor protein-Bace1 clustering in lipid rafts and rapid endocytosis. FASEB J. 2011, 25:1295-1305.
70. Steiner H., Fluhrer R., Haass C. Intramembrane proteolysis by gamma-secretase. J. Biol. Chem. 2008, 283:29627-29631.
71. Crump C.J., Johnson D.S., Li Y.M. Development and mechanism of gamma-secretase modulators for Alzheimer's disease. Biochemistry 2013, (in press) (ahead of print).
72. Tate B., McKee T.D., Loureiro R.M., Dumin J.A., Xia W., Pojasek K., Austin W.F., Fuller N.O., Hubbs J.L., Shen R., Jonker J., Ives J., Bronk B.S. Modulation of gamma-secretase for the treatment of Alzheimer's disease. Int. J. Alzheimers Dis. 2012, 2012:210756.
73. Weidner A.M., Bradley M.A., Beckett T.L., Niedowicz D.M., Dowling A.L., Matveev S.V., LeVine H., Lovell M.A., Murphy M.P. RNA oxidation adducts 8-OHG and 8-OHA change with Abeta42 levels in late-stage Alzheimer's disease. PLoS One 2011, 6:e24930.
74. Markesbery W.R., Lovell M.A. DNA oxidation in Alzheimer's disease. Antioxid. Redox Signal. 2006, 8:2039-2045.
75. Butterfield D.A., Castegna A., Lauderback C.M., Drake J. Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death. Neurobiol. Aging 2002, 23:655-664.
76. Butterfield D.A., Drake J., Pocernich C., Castegna A. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol. Med. 2001, 7:548-554.
77. Markesbery W.R. Oxidative stress hypothesis in Alzheimer's disease. Free Radic. Biol. Med. 1997, 23:134-147.
78. Tamaoka A. Characterization of amyloid beta protein species in the plasma, cerebrospinal fluid and brains of patients with Alzheimer's disease. Nippon Ronen Igakkai Zasshi 1998, 35:273-277.
79. Gustafson D.R., Skoog I., Rosengren L., Zetterberg H., Blennow K. Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women. J. Neurol. Neurosurg. Psychiatry 2007, 78:461-464.
80. Glabe C.C. Amyloid accumulation and pathogensis of Alzheimer's disease: significance of monomeric, oligomeric and fibrillar Abeta. Subcell. Biochem. 2005, 38:167-177.
81. Walsh D.M., Selkoe D.J. Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept. Lett. 2004, 11:213-228.
82. Tomic J.L., Pensalfini A., Head E., Glabe C.G. Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol. Dis. 2009, 35:352-358.
83. Bao F., Wicklund L., Lacor P.N., Klein W.L., Nordberg A., Marutle A. Different beta-amyloid oligomer assemblies in Alzheimer brains correlate with age of disease onset and impaired cholinergic activity. Neurobiol. Aging 2012, 33(825):e821-813.
84. Butterfield D.A., Swomley A.M., Sultana R. Amyloid beta-peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression. Antioxid. Redox Signal. 2013, 19:823-835.
85. Kanski J., Aksenova M., Schoneich C., Butterfield D.A. Substitution of isoleucine-31 by helical-breaking proline abolishes oxidative stress and neurotoxic properties of Alzheimer's amyloid beta-peptide. Free Radic. Biol. Med. 2002, 32:1205-1211.
86. Butterfield D.A., Kanski J. Methionine residue 35 is critical for the oxidative stress and neurotoxic properties of Alzheimer's amyloid beta-peptide 1-42. Peptides 2002, 23:1299-1309.
87. Butterfield D.A., Sultana R. Methionine-35 of abeta(1-42): importance for oxidative stress in Alzheimer disease. J. Amino Acids 2011, 2011:198430.
88. Kanski J., Aksenova M., Butterfield D.A. The hydrophobic environment of Met35 of Alzheimer's Abeta(1-42) is important for the neurotoxic and oxidative properties of the peptide. Neurotox. Res. 2002, 4:219-223.
89. Yatin S.M., Varadarajan S., Link C.D., Butterfield D.A. In vitro and in vivo oxidative stress associated with Alzheimer's amyloid beta-peptide (1-42). Neurobiol. Aging 1999, 20:325-330. (discussion 339-342).
90. Murray M.M., Bernstein S.L., Nyugen V., Condron M.M., Teplow D.B., Bowers M.T. Amyloid beta protein: Abeta40 inhibits Abeta42 oligomerization. J. Am. Chem. Soc. 2009, 131:6316-6317.
91. Clementi M.E., Pezzotti M., Orsini F., Sampaolese B., Mezzogori D., Grassi C., Giardina B., Misiti F. Alzheimer's amyloid beta-peptide (1-42) induces cell death in human neuroblastoma via Bax/bcl-2 ratio increase: an intriguing role for methionine 35. Biochem. Biophys. Res. Commun. 2006, 342:206-213.
92. Dai X.L., Sun Y.X., Jiang Z.F. Attenuated cytotoxicity but enhanced betafibril of a mutant amyloid beta-peptide with a methionine to cysteine substitution. FEBS Lett. 2007, 581:1269-1274.
93. Robinson R.A., Lange M.B., Sultana R., Galvan V., Fombonne J., Gorostiza O., Zhang J., Warrier G., Cai J., Pierce W.M., Bredesen D.E., Butterfield D.A. Differential expression and redox proteomics analyses of an Alzheimer disease transgenic mouse model: effects of the amyloid-beta peptide of amyloid precursor protein. Neuroscience 2011, 177:207-222.
94. Butterfield D.A., Galvan V., Lange M.B., Tang H., Sowell R.A., Spilman P., Fombonne J., Gorostiza O., Zhang J., Sultana R., Bredesen D.E. In vivo oxidative stress in brain of Alzheimer disease transgenic mice: Requirement for methionine 35 in amyloid beta-peptide of APP. Free Radic. Biol. Med. 2010, 48:136-144.
95. Pike C.J., Walencewicz-Wasserman A.J., Kosmoski J., Cribbs D.H., Glabe C.G., Cotman C.W. Structure-activity analyses of beta-amyloid peptides: contributions of the beta 25-35 region to aggregation and neurotoxicity. J. Neurochem. 1995, 64:253-265.
96. Varadarajan S., Kanski J., Aksenova M., Lauderback C., Butterfield D.A. Different mechanisms of oxidative stress and neurotoxicity for Alzheimer's A beta(1-42) and A beta(25-35). J. Am. Chem. Soc. 2001, 123:5625-5631.
97. Tyers M., Mann M. From genomics to proteomics. Nature 2003, 422:193-197.
98. Butterfield D.A., Perluigi M., Reed T., Muharib T., Hughes C.P., Robinson R.A., Sultana R. Redox proteomics in selected neurodegenerative disorders: from its infancy to future applications. Antioxid. Redox Signal. 2012, 17:1610-1655.
99. Sultana R., Butterfield D.A. Oxidative modification of brain proteins in Alzheimer's disease: perspective on future studies based on results of redox proteomics studies. J. Alzheimers Dis. 2013, 33:S243-S251.
100. Butterfield D.A., Gu L., Robinson R.A.S., Di Domenico F. Mass spectrometry and redox proteomics: applications in disease. Mass Spectrom. Rev. 2013, (in press).
101. Hensley K., Carney J.M., Mattson M.P., Aksenova M., Harris M., Wu J.F., Floyd R.A., Butterfield D.A. A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:3270-3274.
102. Butterfield D.A., Hensley K., Harris M., Mattson M., Carney J. beta-Amyloid peptide free radical fragments initiate synaptosomal lipoperoxidation in a sequence-specific fashion: implications to Alzheimer's disease. Biochem. Biophys. Res. Commun. 1994, 200:710-715.
103. Foldi I., Datki Z.L., Szabo Z., Bozso Z., Penke B., Janaky T. Proteomic study of the toxic effect of oligomeric Abeta1-42 in situ prepared from 'iso-Abeta1-42'. J. Neurochem. 2011, 117:691-702.
104. Boyd-Kimball D., Sultana R., Poon H.F., Mohmmad-Abdul H., Lynn B.C., Klein J.B., Butterfield D.A. Gamma-glutamylcysteine ethyl ester protection of proteins from Abeta(1-42)-mediated oxidative stress in neuronal cell culture: a proteomics approach. J. Neurosci. Res. 2005, 79:707-713.
105. Sultana R., Newman S.F., Abdul H.M., Cai J., Pierce W.M., Klein J.B., Merchant M., Butterfield D.A. Protective effect of D609 against amyloid-beta1-42-induced oxidative modification of neuronal proteins: redox proteomics study. J. Neurosci. Res. 2006, 84:409-417.
106. Thomas S.N., Soreghan B.A., Nistor M., Sarsoza F., Head E., Yang A.J. Reduced neuronal expression of synaptic transmission modulator HNK-1/neural cell adhesion molecule as a potential consequence of amyloid beta-mediated oxidative stress: a proteomic approach. J. Neurochem. 2005, 92:705-717.
107. Boyd-Kimball D., Sultana R., Mohmmad-Abdul H., Butterfield D.A. Rodent Abeta(1-42) exhibits oxidative stress properties similar to those of human Abeta(1-42): implications for proposed mechanisms of toxicity. J. Alzheimers Dis. 2004, 6:515-525.
108. Di Francesco L., Correani V., Fabrizi C., Fumagalli L., Mazzanti M., Maras B., Schinina M.E. 14-3-3Epsilon marks the amyloid-stimulated microglia long-term activation. Proteomics 2012, 12:124-134.
109. Drake J., Link C.D., Butterfield D.A. Oxidative stress precedes fibrillar deposition of Alzheimer's disease amyloid beta-peptide (1-42) in a transgenic Caenorhabditis elegans model. Neurobiol. Aging 2003, 24:415-420.
110. Boyd-Kimball D., Poon H.F., Lynn B.C., Cai J., Pierce W.M., Klein J.B., Ferguson J., Link C.D., Butterfield D.A. Proteomic identification of proteins specifically oxidized in Caenorhabditis elegans expressing human Abeta(1-42): implications for Alzheimer's disease. Neurobiol. Aging 2006, 27:1239-1249.
111. Anantharaman M., Tangpong J., Keller J.N., Murphy M.P., Markesbery W.R., Kiningham K.K., St Clair D.K. Beta-amyloid mediated nitration of manganese superoxide dismutase: implication for oxidative stress in a APPNLH/NLH X PS-1P264L/P264L double knock-in mouse model of Alzheimer's disease. Am. J. Pathol. 2006, 168:1608-1618.
112. Abdul H.M., Sultana R., St Clair D.K., Markesbery W.R., Butterfield D.A. Oxidative damage in brain from human mutant APP/PS-1 double knock-in mice as a function of age. Free Radic. Biol. Med. 2008, 45:1420-1425.
113. Huang Q., Aluise C.D., Joshi G., Sultana R., St Clair D.K., Markesbery W.R., Butterfield D.A. Potential in vivo amelioration by N-acetyl-l-cysteine of oxidative stress in brain in human double mutant APP/PS-1 knock-in mice: toward therapeutic modulation of mild cognitive impairment. J. Neurosci. Res. 2010, 88:2618-2629.
114. Robinson R.A., Joshi G., Huang Q., Sultana R., Baker A.S., Cai J., Pierce W., St Clair D.K., Markesbery W.R., Butterfield D.A. Proteomic analysis of brain proteins in APP/PS-1 human double mutant knock-in mice with increasing amyloid beta-peptide deposition: insights into the effects of in vivo treatment with N-acetylcysteine as a potential therapeutic intervention in mild cognitive impairment and Alzheimer's disease. Proteomics 2011, 11:4243-4256.
115. Sultana R., Robinson R.A., Di Domenico F., Abdul H.M., St Clair D.K., Markesbery W.R., Cai J., Pierce W.M., Butterfield D.A. Proteomic identification of specifically carbonylated brain proteins in APP(NLh)/APP(NLh)×PS-1(P264L)/PS-1(P264L) human double mutant knock-in mice model of Alzheimer disease as a function of age. J. Proteome 2011, 74:2430-2440.
116. Yagi H., Katoh S., Akiguchi I., Takeda T. Age-related deterioration of ability of acquisition in memory and learning in senescence accelerated mouse: SAM-P/8 as an animal model of disturbances in recent memory. Brain Res. 1988, 474:86-93.
117. Butterfield D.A., Poon H.F. The senescence-accelerated prone mouse (SAMP8): a model of age-related cognitive decline with relevance to alterations of the gene expression and protein abnormalities in Alzheimer's disease. Exp. Gerontol. 2005, 40:774-783.
118. Poon H.F., Castegna A., Farr S.A., Thongboonkerd V., Lynn B.C., Banks W.A., Morley J.E., Klein J.B., Butterfield D.A. Quantitative proteomics analysis of specific protein expression and oxidative modification in aged senescence-accelerated-prone 8 mice brain. Neuroscience 2004, 126:915-926.
119. Shi X., Lu X., Zhan L., Liu L., Sun M., Gong X., Sui H., Niu X., Liu S., Zheng L., Chen J., Zhou Y. Rat hippocampal proteomic alterations following intrahippocampal injection of amyloid beta peptide (1-40). Neurosci. Lett. 2011, 500:87-91.
120. Yang G.F., Wang L.N., Zhao X., Nie Y.H. Two-dimensional electrophoregram for proteomic analysis of rat brain with intrahippocampal amyloid beta injection and normal rat brain. Di Yi Jun Yi Da Xue Xue Bao 2004, 24:553-555.
121. Sultana R., Boyd-Kimball D., Cai J., Pierce W.M., Klein J.B., Merchant M., Butterfield D.A. Proteomics analysis of the Alzheimer's disease hippocampal proteome. J. Alzheimers Dis. 2007, 11:153-164.
122. Woltjer R.L., Cimino P.J., Boutte A.M., Schantz A.M., Montine K.S., Larson E.B., Bird T., Quinn J.F., Zhang J., Montine T.J. Proteomic determination of widespread detergent-insolubility including Abeta but not tau early in the pathogenesis of Alzheimer's disease. FASEB J. 2005, 19:1923-1925.
123. Sultana R., Poon H.F., Cai J., Pierce W.M., Merchant M., Klein J.B., Markesbery W.R., Butterfield D.A. Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach. Neurobiol. Dis. 2006, 22:76-87.
124. Castegna A., Aksenov M., Aksenova M., Thongboonkerd V., Klein J.B., Pierce W.M., Booze R., Markesbery W.R., Butterfield D.A. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase l-1. Free Radic. Biol. Med. 2002, 33:562-571.
125. Castegna A., Aksenov M., Thongboonkerd V., Klein J.B., Pierce W.M., Booze R., Markesbery W.R., Butterfield D.A. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71. J. Neurochem. 2002, 82:1524-1532.
126. Yoshida H., Watanabe A., Ihara Y. Collapsin response mediator protein-2 is associated with neurofibrillary tangles in Alzheimer's disease. J. Biol. Chem. 1998, 273:9761-9768.
127. Li T., Hawkes C., Qureshi H.Y., Kar S., Paudel H.K. Cyclin-dependent protein kinase 5 primes microtubule-associated protein tau site-specifically for glycogen synthase kinase 3beta. Biochemistry-US 2006, 45:3134-3145.
128. Cole A.R., Noble W., van Aalten L., Plattner F., Meimaridou R., Hogan D., Taylor M., LaFrancois J., Gunn-Moore F., Verkhratsky A., Oddo S., LaFerla F., Giese K.P., Dineley K.T., Duff K., Richardson J.C., Yan S.D., Hanger D.P., Allan S.M., Sutherland C. Collapsin response mediator protein-2 hyperphosphorylation is an early event in Alzheimer's disease progression. J. Neurochem. 2007, 103:1132-1144.
129. Butterfield D.A., Lange M.L. Multifunctional roles of enolase in Alzheimer's disease brain: beyond altered glucose metabolism. J. Neurochem. 2009, 111:915-933.
130. Butterfield D.A., Hardas S.S., Lange M.L. Oxidatively modified glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and Alzheimer's disease: many pathways to neurodegeneration. J. Alzheimers Dis. 2010, 20:369-393.
131. Hoyer S. Brain glucose and energy metabolism abnormalities in sporadic Alzheimer disease. Causes and consequences: an update. Exp. Gerontol. 2000, 35:1363-1372.
132. Engelhart M.J., Geerlings M.I., Ruitenberg A., van Swieten J.C., Hofman A., Witteman J.C., Breteler M.M. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 2002, 287:3223-3229.
133. Luchsinger J.A., Tang M.X., Shea S., Mayeux R. Antioxidant vitamin intake and risk of Alzheimer disease. Arch. Neurol. 2003, 60:203-208.
134. Petersen R.C., Thomas R.G., Grundman M., Bennett D., Doody R., Ferris S., Galasko D., Jin S., Kaye J., Levey A., Pfeiffer E., Sano M., van Dyck C.H., Thal L.J. Vitamin E and donepezil for the treatment of mild cognitive impairment. N. Engl. J. Med. 2005, 352:2379-2388.
135. Joshi G., Perluigi M., Sultana R., Agrippino R., Calabrese V., Butterfield D.A. In vivo protection of synaptosomes by ferulic acid ethyl ester (FAEE) from oxidative stress mediated by 2,2-azobis(2-amidino-propane)dihydrochloride (AAPH) or Fe(2+)/H(2)O(2): insight into mechanisms of neuroprotection and relevance to oxidative stress-related neurodegenerative disorders. Neurochem. Int. 2006, 48:318-327.
136. Grossi C., Rigacci S., Ambrosini S., Ed Dami T., Luccarini I., Traini C., Failli P., Berti A., Casamenti F., Stefani M. The polyphenol oleuropein aglycone protects TgCRND8 mice against ass plaque pathology. PLoS One 2013, 8:e71702.
137. Finehout E.J., Franck Z., Choe L.H., Relkin N., Lee K.H. Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease. Ann. Neurol. 2007, 61:120-129.
138. Henkel A.W., Muller K., Lewczuk P., Muller T., Marcus K., Kornhuber J., Wiltfang J. Multidimensional plasma protein separation technique for identification of potential Alzheimer's disease plasma biomarkers: a pilot study. J. Neural Transm. 2012, 119:779-788.
139. Sultana R., Mecocci P., Mangialasche F., Cecchetti R., Baglioni M., Butterfield D.A. Increased protein and lipid oxidative damage in mitochondria isolated from lymphocytes from patients with Alzheimer's disease: insights into the role of oxidative stress in Alzheimer's disease and initial investigations into a potential biomarker for this dementing disorder. J. Alzheimers Dis. 2011, 24:77-84.
140. Sultana R., Baglioni M., Cecchetti R., Cai J., Klein J.B., Bastiani P., Ruggiero C., Mecocci P., Butterfield D.A. Lymphocyte mitochondria: toward identification of peripheral biomarkers in the progression of Alzheimer disease. Free Radic. Biol. Med. 2013, 65:595-606.
141. Di Domenico F., Coccia R., Butterfield D.A., Perluigi M. Circulating biomarkers of protein oxidation for Alzheimer disease: expectations within limits. Biochim. Biophys. Acta 2011, 1814:1785-1795.
142. Bachi A., Dalle-Donne I., Scaloni A. Redox proteomics: chemical principles, methodological approaches and biological/biomedical promises. Chem. Rev. 2013, 113:596-698.
143. Vemuri P., Lesnick T.G., Przybelski S.A., Knopman D.S., Roberts R.O., Lowe V.J., Kantarci K., Senjem M.L., Gunter J.L., Boeve B.F., Petersen R.C., Jack C.R. Effect of lifestyle activities on Alzheimer disease biomarkers and cognition. Ann. Neurol. 2012, 72:730-738.
144. Dao A.T., Zagaar M.A., Levine A.T., Salim S., Eriksen J.L., Alkadhi K.A. Treadmill exercise prevents learning and memory impairment in Alzheimer's disease-like pathology. Curr. Alzheimer Res. 2013, 10:507-515.
145. Shah R. The role of nutrition and diet in Alzheimer disease: a systematic review. J. Am. Med. Dir. Assoc. 2013, 14:398-402.